Clayton Larsen - President & CEO, Vesselon, Inc. | Oct 30, 2023 | 4 min read
Vesselon’s novel co-formulation of gas lipid microspheres and self-assembling liposomes, targeted and activated by commercial ultrasound, would be an ideal adjunct to any of these ADC drugs.
By packaging lipid nanoparticles with elements that decrease the fibrous nature of solid tumors, researchers can deliver CRISPR therapies in a more efficient manner.
A vaccine strategy involving formulation changes, an initial escalating dose, and a longer wait for booster immunization results in more-effective antibody production against HIV in rhesus monkeys, a study finds.